Nitrous oxide-better known as "laughing gas"-can potentially transform treatment for tough-to-beat depression.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Although a plethora of medications and therapies now exist for major depression, roughly one in three diagnosed patients ...

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company ...

A new study published in the Journal of Affective Disorders has found that adults with major depression show specific ...

A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...

Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...